J9226 Supprelin la implant
Also known as: leuprolide, Supprelin LA
Subcutaneous implant of leuprolide acetate (Supprelin LA brand), a gonadotropin-releasing hormone (GnRH) agonist.
In Plain Language
hormone-blocking implant; precocious puberty treatment
Clinical Context
Brand-specific long-acting implant for central precocious puberty in pediatric patients.
RVU Information
CPT J9226 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9226?
CPT J9226 (Supprelin la implant) is a J Codes (Drugs) code. Subcutaneous implant of leuprolide acetate (Supprelin LA brand), a gonadotropin-releasing hormone (GnRH) agonist.
How is J9226 administered?
CPT J9226 is administered by a healthcare provider, typically via injection or infusion. Brand-specific long-acting implant for central precocious puberty in pediatric patients. It is used by Pediatric Oncology, Endocrinology.
When is CPT J9226 used?
Brand-specific long-acting implant for central precocious puberty in pediatric patients.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.